Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.72 |
| ▸ | CHRNA5 | P30532 | 3/20 | 0.72 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.72 |
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | GRM5 | P41594 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2043397 | 0.89 | NPC1 (0.73) | CHRNB2CHRNA5CHRNA4NPC1RAB9A | |
| SCHEMBL2040629 | 0.86 | NPC1 (0.51) | CHRNB2CHRNA5CHRNA4NPC1RAB9A | |
| SCHEMBL2037066 | 0.84 | CHRNB2 (0.72) | CHRNB2CHRNA5CHRNA4NPC1RAB9A | |
| SCHEMBL2040333 | 0.84 | CHRNB2 (0.72) | CHRNB2CHRNA5CHRNA4NPC1RAB9A | |
| SCHEMBL2034759 | 0.81 | NPC1 (0.51) | CHRNB2CHRNA5CHRNA4NPC1RAB9A | |
| SCHEMBL2038504 | 0.79 | RAB9A (0.53) | CHRNB2CHRNA5CHRNA4NPC1RAB9A | |
| SCHEMBL2120756 | 0.79 | CHRNB2 (0.71) | CHRNB2CHRNA5CHRNA4NPC1RAB9A | |
| SCHEMBL2033604 | 0.78 | CHRNB2 (0.72) | CHRNB2CHRNA5CHRNA4NPC1RAB9A | |
| SCHEMBL2037580 | 0.77 | NPC1 (0.46) | CHRNB2CHRNA5CHRNA4NPC1RAB9A | |
| SCHEMBL3752704 | 0.76 | CHRNB2 (0.73) | CHRNB2CHRNA5CHRNA4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309792-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2012-12-06 | — | — | US | claimed |
| EP-2513087-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MOUDLATORS | NeuroSearch A/S (DK) | 2012-10-24 | — | — | EP | claimed |
| WO-2011073297-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MOUDLATORS | NEUROSEARCH A/S (DK) | 2011-06-23 | — | — | WO | claimed |
| US-20120309792-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2012-12-06 | — | — | US | disclosed |
| EP-2513087-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MOUDLATORS | NeuroSearch A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073297-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MOUDLATORS | NEUROSEARCH A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309792-A1 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA5, CHRNA7, CHRNA3 | CHRNB2 13/4885CHRNA5 1/4885CHRNA4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.